LeonaBio director granted 28,000 stock options

LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation.

Rhea-AI Filing Summary

LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation. He was awarded 28,000 stock options to acquire LeonaBio common stock at an exercise price of $8.35 per share. The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, and expire on June 22, 2036. Following this grant, Johnson holds 28,000 options to purchase LeonaBio common stock directly.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider JOHNSON JAMES A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Key Figures

Option grant size: 28,000 options Exercise price: $8.35 per share Options after transaction: 28,000 options +3 more

6 metrics

Option grant size 28,000 options Stock Option (Right to Buy) grant to director

Exercise price $8.35 per share Conversion or exercise price of granted options

Options after transaction 28,000 options Total options following transaction (direct holding)

Vesting date trigger June 23, 2027 Latest vesting date, subject to earlier annual meeting condition

Alternative vesting condition date After June 22, 2026 Next annual meeting timing reference for earlier vesting

Option expiration date June 22, 2036 Expiration of Stock Option (Right to Buy)

Key Terms

Stock Option (Right to Buy), Outside Director Compensation Policy, vest

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Outside Director Compensation Policy financial

"The option was granted pursuant to the Issuer's Outside Director Compensation Policy"

vest financial

"The shares subject to the option will vest on the earlier of June 23, 2027, or before the next annual meeting"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LeonaBio (LONA) director James A. Johnson report on this Form 4?

James A. Johnson reported receiving a grant of 28,000 stock options in LeonaBio, Inc. The options give him the right to buy LeonaBio common stock at a fixed exercise price as part of the company’s Outside Director Compensation Policy.

How many LeonaBio (LONA) stock options did the director receive and at what price?

He received 28,000 stock options with an exercise price of $8.35 per share. This means he can purchase up to 28,000 shares of LeonaBio common stock at $8.35, regardless of the market price when he exercises the options.

When do James A. Johnson’s LeonaBio (LONA) stock options vest?

The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Vesting must occur before he can exercise the options and purchase the underlying shares.

When do the LeonaBio (LONA) stock options granted to the director expire?

The options expire on June 22, 2036. After this expiration date, any unexercised options will lapse, and he will no longer have the right to purchase LeonaBio common stock under this specific grant.

Is this LeonaBio (LONA) Form 4 grant an open-market purchase or a compensation award?

This transaction is a compensation award, not an open-market purchase. The Form 4 identifies the code as a grant, awarded under LeonaBio’s Outside Director Compensation Policy, meaning it is part of standard director compensation rather than a market trade.

How many LeonaBio (LONA) options does James A. Johnson hold after this transaction?

After the grant, he holds 28,000 stock options directly. These options represent his right to buy LeonaBio common stock at the fixed exercise price, subject to the vesting schedule and the final expiration date in 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON JAMES A

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	06/23/2026		A		28,000		(1)	06/22/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

	/s/ Mark Worthington, Attorney in fact for James A. Johnson	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)